دورية أكاديمية
أعرض في EDS

BRAF Inhibitors in Non-Small Cell Lung Cancer.

التفاصيل البيبلوغرافية
العنوان: BRAF Inhibitors in Non-Small Cell Lung Cancer.
المؤلفون: Sforza V; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Palumbo G; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Cascetta P; Department of Medical Oncology, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France., Carillio G; Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy., Manzo A; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Montanino A; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Sandomenico C; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Costanzo R; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Esposito G; Oncology, San Giuseppe Moscati Hospital, 81031 Aversa, Italy., Laudato F; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Damiano S; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Forte CA; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Frosini G; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Farese S; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Piccirillo MC; Clinical Trials Unit, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Pascarella G; Scientific Directorate, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Normanno N; Cellular Biology and Biotherapy, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy., Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori, 'Fondazione G. Pascale'-IRCCS, 80131 Napoli, Italy.
المصدر: Cancers [Cancers (Basel)] 2022 Oct 05; Vol. 14 (19). Date of Electronic Publication: 2022 Oct 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: RAF family proteins are serine-threonine kinases that play a central role in the MAPK pathway which is involved in embryogenesis, cell differentiation, cell proliferation and death. Deregulation of this pathway is found in up to 30% of all human cancers and BRAF mutations can be identified in 1.5-3.5% of NSCLC patients. Following the positive results obtained through the combination of BRAF and MEK inhibitors in BRAF-mutant melanoma, the same combination was prospectively assessed in BRAF-mutant NSCLC. In cohort B of the BRF113928 trial, 57 pretreated NSCLC patients were treated with dabrafenib plus trametinib: an ORR of 68.4%, a disease control rate of 80.7%, a median PFS of 10.2 months and a median OS of 18.2 months were observed. Similar results were reported in the first-line setting (cohort C), with an ORR of 63.9%, a DCR of 75% and a median PFS and OS of 10.2 and 17.3 months, respectively. The combination was well tolerated: the main adverse events were pyrexia (64%), nausea (56%), diarrhoea (56%), fatigue (36%), oedema (36%) and vomiting (33%). These positive results led to the approval of the combination of dabrafenib and trametinib for the treatment of BRAF V600E metastatic NSCLC patients regardless of previous therapy. Ongoing research should better define the role of new generation RAF inhibitors for patients with acquired resistance, the activity of chemo-immunotherapy or the combination of TKIs with chemotherapy or with immunotherapy in patients with BRAF-mutated cancers.
References: Cancers (Basel). 2021 Apr 30;13(9):. (PMID: 33946519)
N Engl J Med. 2014 Dec 4;371(23):2230-2. (PMID: 25409261)
Cancer Cell. 2010 Mar 16;17(3):221-3. (PMID: 20227037)
Crit Rev Oncol Hematol. 2020 Aug;152:103008. (PMID: 32485528)
JAMA Oncol. 2019 Jul 01;5(7):999-1007. (PMID: 31145415)
J Transl Med. 2019 Aug 30;17(1):298. (PMID: 31470866)
N Engl J Med. 2015 Aug 20;373(8):726-36. (PMID: 26287849)
J Thorac Oncol. 2020 Oct;15(10):1611-1623. (PMID: 32540409)
Lancet Oncol. 2018 May;19(5):603-615. (PMID: 29573941)
Lancet Oncol. 2016 Jul;17(7):984-993. (PMID: 27283860)
Cancer Treat Rev. 2018 May;66:82-94. (PMID: 29729495)
Clin Cancer Res. 2013 Aug 15;19(16):4532-40. (PMID: 23833300)
Ann Oncol. 2019 Aug 1;30(8):1321-1328. (PMID: 31125062)
N Engl J Med. 2012 Feb 23;366(8):707-14. (PMID: 22356324)
Lung Cancer. 2019 Mar;129:80-84. (PMID: 30797497)
N Engl J Med. 2010 Aug 26;363(9):809-19. (PMID: 20818844)
J Thorac Oncol. 2015 Oct;10(10):1451-7. (PMID: 26200454)
J Clin Oncol. 2011 Sep 10;29(26):3574-9. (PMID: 21825258)
Clin Cancer Res. 2015 Apr 15;21(8):1935-43. (PMID: 25351745)
Endocr Rev. 2001 Apr;22(2):153-83. (PMID: 11294822)
Lung Cancer. 2014 Aug;85(2):326-30. (PMID: 24888229)
J Clin Oncol. 2013 Jul 10;31(20):e341-4. (PMID: 23733758)
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. (PMID: 22773810)
J Thorac Oncol. 2020 Apr;15(4):628-636. (PMID: 31945494)
J Thorac Oncol. 2019 Mar;14(3):e57-e59. (PMID: 30782386)
Int J Mol Sci. 2017 Jul 14;18(7):. (PMID: 28708099)
Ann Oncol. 2020 Feb;31(2):289-294. (PMID: 31959346)
Lancet. 2015 Aug 1;386(9992):444-51. (PMID: 26037941)
Cancer Cell. 2015 Jan 12;27(1):85-96. (PMID: 25500121)
JCO Precis Oncol. 2019 Jun 27;3:. (PMID: 32914022)
J Hematol Oncol. 2021 Jan 5;14(1):1. (PMID: 33402199)
N Engl J Med. 2011 Jun 30;364(26):2507-16. (PMID: 21639808)
Nature. 2015 Oct 22;526(7574):583-6. (PMID: 26466569)
Clin Cancer Res. 2019 Jan 1;25(1):158-165. (PMID: 30224342)
N Engl J Med. 2019 Oct 24;381(17):1632-1643. (PMID: 31566309)
Lancet. 2012 May 19;379(9829):1893-901. (PMID: 22608338)
Lancet Oncol. 2016 Sep;17(9):1248-60. (PMID: 27480103)
Pharmacol Res. 2018 Sep;135:239-258. (PMID: 30118796)
J Thorac Oncol. 2022 Jan;17(1):103-115. (PMID: 34455067)
J Biol Chem. 1998 Sep 18;273(38):24939-47. (PMID: 9733801)
J Thorac Oncol. 2013 May;8(5):e41-2. (PMID: 23524406)
Cancer Res. 2008 Jul 15;68(14):5524-8. (PMID: 18632602)
Mol Cell Oncol. 2015 May 26;3(1):e1048929. (PMID: 27308563)
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. (PMID: 30285222)
J Thorac Oncol. 2017 Mar;12(3):567-572. (PMID: 27923714)
Cancer Discov. 2019 Mar;9(3):329-341. (PMID: 30770389)
J Clin Oncol. 2012 Jan 20;30(3):316-21. (PMID: 22067401)
Biochem Biophys Res Commun. 2012 Jan 6;417(1):5-10. (PMID: 22177953)
Cancer Med. 2019 Jun;8(6):2858-2866. (PMID: 31016879)
Drugs Context. 2019 Mar 13;8:212566. (PMID: 30899313)
Clin Lung Cancer. 2017 Nov;18(6):e395-e402. (PMID: 28550959)
Oncogene. 2018 Jun;37(24):3183-3199. (PMID: 29540830)
Int J Mol Sci. 2019 Mar 25;20(6):. (PMID: 30934534)
J Thorac Oncol. 2012 Oct;7(10):e23-4. (PMID: 22743296)
Lancet Oncol. 2016 May;17(5):642-50. (PMID: 27080216)
J Clin Oncol. 2011 May 20;29(15):2046-51. (PMID: 21483012)
Mol Cell Biol. 2006 Mar;26(6):2262-72. (PMID: 16508002)
PLoS One. 2014 Jun 30;9(6):e101354. (PMID: 24979348)
J Thorac Oncol. 2018 Aug;13(8):1128-1137. (PMID: 29723688)
Exp Hematol Oncol. 2017 Nov 06;6:29. (PMID: 29142786)
Eur J Cancer. 2015 Dec;51(18):2792-9. (PMID: 26608120)
Lung Cancer. 2014 Apr;84(1):36-8. (PMID: 24552757)
فهرسة مساهمة: Keywords: BRAF; MEK; NSCLC; binimetinib; dabrafenib; encorafenib; trametinib
تواريخ الأحداث: Date Created: 20221014 Latest Revision: 20221017
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9562258
DOI: 10.3390/cancers14194863
PMID: 36230797
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14194863